Fortrea Holdings Inc. has announced its financial results for the third quarter of 2026, revealing a revenue of $691.5 million and a GAAP net income of $0.6 million. This marks a significant step in the company's return-to-growth strategy, reflecting stronger commercial execution and operational improvements.

For the three months ending September 30, 2026, Fortrea's results indicate a book-to-bill ratio of 1.12x, which is a positive indicator of future revenue growth. The company’s adjusted net income was reported at $27.9 million, translating to an adjusted diluted earnings per share of $0.28. These results demonstrate Fortrea's continued momentum in the medical laboratory services sector.

Background

Fortrea Holdings Inc. operates as a leading global contract research organization (CRO) under the SIC classification of Services-Medical Laboratories (8071). The company trades on the Nasdaq under the ticker FTRE. Fortrea was formerly known as Silver Spinco Inc., with a name change effective February 7, 2023. The company is based in Durham, North Carolina, and is classified as an accelerated filer.

What the Filing Says

According to the recent SEC filing (accession number 0001965040-26-000146), Fortrea announced its financial results for the fiscal quarter ended September 30, 2026. The filing states, "Fortrea delivered another quarter of progress on our return-to-growth strategy, reflecting stronger commercial execution, continued operational improvements and financial discipline." This statement underscores the company's commitment to enhancing its market position.

Impact

The results reported by Fortrea may affect various stakeholders, including investors, employees, and clients in the medical laboratory services sector. The positive financial performance and guidance adjustments could bolster investor confidence and attract potential clients looking for reliable CRO services.

What's Next

The filing does not say what happens next. However, the company has raised the midpoints of its full-year revenue and adjusted EBITDA guidance, indicating a positive outlook for the remainder of 2026.